glp-1 drug delivery devices RETHINKING DEVICES: DESIGNING FOR USERS BEYOND DIABETES GLP-1 Medications: A Comprehensive Overview
Description
The litigation has produced zero settlements so far
G.JonesK
2020;192:E87591
H.ApanovitchA.RavichandranS.ListJ.ChenR.et al (2009)
Altogether, about 1 in 8 US adults say theyre currently taking one of the medicines, according to data from health policy research group KFF
& Makin, V
